This content is machine translated Systemic disease psoriasis Keep an eye on comorbidities Comorbidities may already be present at the initial manifestation of plaque psoriasis, but sometimes these only develop later in the course of the disease. Taking this into account appropriately can…
View Post 4 min This content is machine translated "Psoriasis and Beyond" Insight into the patient’s perspective In order to better understand the experiences and views of patients affected by psoriasis and psoriatic arthritis, a survey of almost 5,000 patients was conducted on four continents worldwide.One focus…
View Post 5 min This content is machine translated Psoriasis: "Awareness" of comorbidities Cardiometabolic diseases and other comorbidities In addition to certain risk and trigger factors, psoriasis is associated with various comorbidities, such as metabolic syndrome, cardiovascular disease, and depression. This is particularly true for patients with moderate…
View Post 4 min This content is machine translated Case series Topical therapy of scalp psoriasis Treatment of the capillitium often presents a particular challenge in topical therapy. In addition to the condition of the skin, the patient’s preferences are also an important criterion in choosing…
View Post 4 min This content is machine translated Psoriasis Tissue-resident memory T cells as “key players”. Immunological memory plays an important role in the pathogenesis of psoriasis. Increasingly, researchers are focusing on tissue resident memory T-cells (TRM cells). This is because the persistence of TRM cells…
View Post 3 min This content is machine translated Routine care for psoriasis Update system therapy – what is important for the practice? The new treatment options lead to higher therapeutic goals. This is also reflected in the current psoriasis guideline, which received an update last year. The determination of the severity is…
View Post 12 min This content is machine translated Axial spondyloarthritis and psoriatic arthritis Effective and efficient against pain The anti-IL-17A monoclonal antibody ixekizumab has already been approved since 2016 for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis. In 2020, axial spondyloarthritis (axSpA) was added… CME-Test
View Post 3 min This content is machine translated Psoriasis: disease management during corona pandemic “Shared decision making” is especially important in these times Among psoriasis patients, there is often some uncertainty about the implications of their underlying disease and the respective system therapy with regard to the risk of a severe course of…
View Post 4 min This content is machine translated Comorbidity Research Psoriasis as a systemic disease – study findings on comorbid depression Psoriasis and psoriatic arthritis (PsoA) often have a significant impact on the daily life and quality of life of those affected. The prevalence of mental health comorbidities is increased, with…
View Post 9 min This content is machine translated Mild to moderate psoriasis vulgaris Swiss treatment pathway for topical psoriasis therapy 2021 Topical treatment of plaque psoriasis has a high priority in the everyday clinical practice. In mild symptoms, topical topical preparations are the mainstay of therapy; in moderate to severe cases, they…
View Post 2 min This content is machine translated Plaque psoriasis Secukinumab ready-to-use 300 mg injection convinces The EMA-approved new route of administration for the IL-17A inhibitor allows the recommended dosage to be administered in a single injection. Data analyses of the pivotal phase IIIb MATURE study…
